Results 11 to 12 of about 15 (12)
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. [PDF]
Wu J +23 more
europepmc +1 more source

